Ann: Foundation Fighting Blindness Presentation Materials, page-2

A little piece of info about today's (US time, 2nd May, 2025), Foundation Fighting Blindness conference...

The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases. Join the fight and help us accelerate our mission.

I feel confident that those attending would be most interested and highly delighted with PYC's RP11 progress. In terms of the fight, PYC are in it, boots and all with their cutting edge technology. It will be a huge outcome for those afflicted with RP11 for PYC's registrational trial to be fast tracked based on safety and efficacy data generated thus far. Potentially a gamechanger for many and it's only just over one month from now when we sit down with the FDA to discuss alignment for an accelerated registrational trial.

AND NEXT....

On Monday, (Monday US time), PYC will also be exhibiting at the 2025 ARVO Meeting/Conference. This is a biggie, it goes for four days and is very well attended. Last year ARVO drew 11,400 people which included basic science researchers, clinical researchers, clinicians, surgeons, ophthalmology educators and students, and clinicians-in-training. Top fields of study and practice of attendees include retina, cornea, glaucoma, retinal cell biology, age-related macular degeneration, diabetic retinopathy, cataracts, dry eye, basic research and clinical private practice.

Membership of ARVO is approximately 11,000 and extends to 65 countries, ARVO is significant with its global footprint and typically their annual meeting attracts around 80% of members. Exhibitors like PYC, would have a booth amongst other relevant sponsors who would undoubtedly represent the who's who of the Industry. There are Meeting Suites available for exhibitors to facilitate important and possibly private interactions, and overall the Conference itself has an agenda of many session type meetings for attendees covering subjects of particular interest. I'm not sure if PYC how the session type meetings may or may not involve PYC, I couldn't track down that info from the public domain.

With the ARVO 2025 exposure PYC has a terrific opportunity to shine its light, with some truly remarkable and significant safety and efficacy data relating to RP11, and with a further note that PYC's has also commenced in-human clinical trials for ADOA so in theory PYC's RP11 growing success may be somewhat of a catalyst for increased validation of our technology and capability across so much more in the overall field eye diseases.

Makes me wonder what those discussions might be like in those private meeting rooms at ARVO 2025, maybe an anchoring point to take BD interest to the next level?